Mismatched double-stranded RNA: PolyI:PolyC12U

Drugs in R and D

Volumn 5, Issue 5, 2004, Pages 297-304

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALPHAN3 INTERFERON; AMPLIGEN; AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIGEN P24; CELL ENZYME; DELAVIRDINE; DIDANOSINE; DOUBLE STRANDED RNA; EFAVIRENZ; IMMUNOMODULATING AGENT; INDINAVIR; INTERFERON; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; ORAGENS; ORPHAN DRUG; PEGINTERFERON; RITONAVIR; RNA LIGASE; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANDORRA; ANTIVIRAL ACTIVITY; ARTICLE; AUSTRALIA; AUSTRIA; BIOLOGICAL WARFARE; BLOOD FLOW; BRAIN; CANADA; CELL DESTRUCTION; CHILL; CHINA; CHRONIC FATIGUE SYNDROME; CLINICAL PROTOCOL; CLINICAL STUDY; CLINICAL TRIAL; COMMERCIAL PHENOMENA; CONCENTRATION RESPONSE; CORONAVIRUS; COST BENEFIT ANALYSIS; COXSACKIE VIRUS B3; CYTOKINE PRODUCTION; CZECH REPUBLIC; DENGUE VIRUS; DISEASE SEVERITY; DISORDERS OF ACID BASE BALANCE; DRUG ANTAGONISM; DRUG FORMULATION; DRUG INDICATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DYSPNEA; ENZYME ACTIVATION; EPSTEIN BARR VIRUS; EUROPEAN UNION; FATIGUE; FEE; FEVER; FINANCIAL MANAGEMENT; FLAVIVIRUS; FLU LIKE SYNDROME; FLUSHING; GERMANY; HEADACHE; HEALTH CARE ORGANIZATION; HEALTH PROGRAM; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUNGARY; HYPERLIPIDEMIA; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOPATHOLOGY; INSULIN RESISTANCE; IRELAND; JAPANESE ENCEPHALITIS VIRUS; KIDNEY CARCINOMA; LACTATE BLOOD LEVEL; LEUKOCYTOSIS; LEUKOPENIA; LICENSING; MELANOMA; MULTIDRUG RESISTANCE; MYALGIA; NAUSEA; NERVE CELL; NONHUMAN; ORGANIZATION; PATENT; POLAND; PORTUGAL; PRIORITY JOURNAL; PUBLISHING; RELAPSE; SEVERE ACUTE RESPIRATORY SYNDROME; SKIN MANIFESTATION; SOUTH AFRICA; SPAIN; SUPERINFECTION; SURVIVAL RATE; SWITZERLAND; T LYMPHOCYTE ACTIVATION; THORAX DISEASE; UNITED KINGDOM; UNITED STATES; VIRUS MUTATION; VIRUS MYOCARDITIS; VIRUS STRAIN; WEST NILE FLAVIVIRUS; WESTERN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS;

ANIMALS; ANTI-HIV AGENTS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; BASE PAIR MISMATCH; DRUG INTERACTIONS; HEPATITIS B; HUMANS; MICE; NERVOUS SYSTEM DISEASES; POLY I-C; POLY U; RNA, DOUBLE-STRANDED; VIRUS DISEASES;

EID: 7244242469     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200405050-00006     Document Type: Article

References (31)

1. Hemispherx Biopharma Inc. Hemispherx Biopharma Signs Option Agreement for Ampligen with Fujisawa Pharmaceutical Company. Media Release: 18 Feb 2004. Available from URL: http://www.hemispherx.net
2. Hemispherx Biopharma Inc. Hemispherx Biopharma Signs Agreement with Guangdong Medicine Group Corporation. Media Release: 4 Sep 2003. Available from URL: http://www.hemispherx.net
3. Hemispherx Biopharma Inc. Hemispherx Biopharma Enters Into Therapeutic Agreement for Ampligen® With The Center for Cell and Gene Therapy at Baylor College of Medicine. Media Release: 5 May 2003. Available from URL: http://www.hemispherx.net
4. Hemispherx Biopharma Inc. SARS: Newly NIH Sponsored Studies of Potential Therapies for SARS Now Finds Hemispherx' Ampligen among the Most Active from a Large Pool of 70 - Seventy - Drug Candidates. Media Release: 21 May 2003. Available from URL: http://www.hemispherx.net
5. Hemispherx Biopharma Inc. Hemispherx Biopharma Expands SARS Prevention/Treatment Initiative; Prior to Anticipated Fall/Winter Outbreak also widens Distribution and Clinical Networks. Media Release: 14 Oct 2003. Available from URL: http://www.hemispherx.net
6. Hemispherx Biopharma Inc. Hemispherx Reports Ampligen Prevents Destruction of Nerve Cells and Increases Survival Rates in Flavivirus Infection. Media Release: 29 Jul 2003. Available from URL: http://www.hemispherx.net
7. Hemispherx Biopharma Inc. Hemispherx Biopharma Reports Publication Suggesting Efficacy of Ampligen in Treating Myo-carditis Virus. Media Release: 26 Jan 2004. Available from URL: http://www.hemispherx.net
8. McMahon D, Winkelstein A, Huang X-L, et al. Acute reactions associated with the infusion of ampligen. AIDS 6: 235-236, Feb 1992
9. Armstrong JA, McMahon D, Huang X-L, et al. A phase I study of ampligen in human immunodeficiency virus-infected subjects. Journal of Infectious Diseases 166: 717-722, Oct 1992
10. Hendrix CW, Margolick JB. Petty BG. et al. Biologic effects after a single dose of poly(I):poly(C12U) in healthy volunteers. Antimicrobial Agents and Chemotherapy 37: 429-435, Mar 1993
11. Gillespie D. Hubbell HR. Carter WA. et al. Synergistic inhibition of AZT-resistant HIV by AZT combined with poly(I):poly(C12U), without synergistic toxicity to bone marrow progenitor cell elements. In Vivo 8: 375-381, May-Jun 1994
12. Thompson KA, Strayer DR, Salvato PD, et al. Results of a double-blind placebo-controlled study of the double-stranded RNA drug polyI:polyC(12)U in the treatment of HIV infection. European Journal of Clinical Microbiology and Infectious Diseases 15: 580-587, Jul 1996
13. Strayer D, Blick G, Mitchell W, et al. A phase IIB prospective, randomized, controlled study evaluating the immunomodulatory role of poly I:poly C12U against HIV. 14th International Aids Conference Supplement: 37, 7 Jul 2002
14. Buzaid AC, Strayer DR, Witman PA. Phase I/II study of poly I:polyC(12)U (Ampligen®) shows activity against metastatic melanoma. Proceedings of the American Society of Clinical Oncology 13: 399, Mar 1994
15. Essey RJ, McDougall BR, Robinson WE. Mismatched double-stranded RNA (PolyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro. Antiviral Research 51: 189-202, Sep 2001
16. Niu J, Wang Y, Dixon R. The use of ampligen alone and in combination with ganciclovir and coumermycin A1 for the treatment of ducks congenitally-infected with duck hepatitis B virus. Antiviral Research 21: 155-171, Jun 1993
17. Suhadolnik RJ, Reichenbach NL, Hitzges P, et al. Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome. Clinical Infectious Diseases 18 (Suppl.1): 96-104, Jan 1994
18. Ushijima H, Tsiapalis CM, Daum T, et al. Synergistic antihuman immunodeficiency viral (HIV-1) effect of the immunomodulator ampligen (mismatched double-stranded RNA) with inhibitors of reverse transcriptase and HIV-1 regulatory proteins. Antiviral Chemistry and Chemotherapy 4: 315-321, No. 6, 1993
19. O'Marro SD, Armstrong JA, Asuncion C, et al. The effect of combinations of ampligen and zidovudine or dideoxyinosine against human immunodeficiency viruses in vitro. Antiviral Research 17: 169-177, Feb 1992
20. Ablashi DV, Berneman Z, Strayer DR. Poly(I):poly(C12U) inhibits in vitro replication of human herpesvirus type 6. Clinical Infectious Diseases 18 (Suppl.1): 113, Jan 1994
21. Ablashi DV, Berneman ZN, Williams M, et al. Ampligen inhibits human herpesvirus-6 in vitro. In Vivo 8: 587-591. Jul-Aug 1994
22. Konishi K, Mukoyama A, Müller WEG. Effect of poly(I). poly(C12U) (Ampligen) on enteric virus (rotavirus, poliovirus and Coxsackie B3 virus) infections. Letters in Applied Microbiology 19: 386-390, Nov 1994
23. Hemispherx Biopharma Inc. Hemispherx Biopharma Announces Phase 3 Chronic Fatigue Syndrome Trial Meets Primary Endpoint. Media Release: 3 May 2004. Available from URL: http://www.hemispherx.net
24. Carter W, Strayer D, Mitchell W, et al. Phase III, randomized, double-blinded clinical trial in chronic fatigue syndrome shows significant improvement in exercise treadmill performance with ampligen compared to placebo. 17th International Conference on Antiviral Research: Late Breakers: 13, May 2004
25. Strayer DR, Carter WA, Brodsky I. A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome. Clinical Infectious Diseases 18 (Suppl.1): 88-95, Jan 1994
26. Hemispherx Biopharma Inc. Belgian study reports good results, trial is expanded. Media Release: 27 Nov 1996. Available from URL: http://www.hemispherx.net
27. Helix BioPharma Corporation. Belgium Clinical Trial Demonstrates that Ampligen® is Effective in the Treatment of Chronic Fatigue Syndrome. Media Release: 17 Oct 1996. Available from URL: http://www.helixbio.com
28. O'Brien CB, Garcia G, Henzel B. Ampligen treatment of chronic hepatitis B. Gastroenterology 106 (Suppl.): 952, Apr 1994
29. Hemispherx Biopharma Inc. Hemispherx announces poly I: poly C12U increases the control of HIV during strategic treatment interruption in chronically HIV infected patients. Media Release [2 pages], 18 Mar 2002. Available from URL: http://www.hemispherx.net
30. Mitchell W, Blick G. Strayer D, et al. A phase IIB prospective, randomized, controlled study evaluating AMPLIGEN during structured treatment interruption of HAART in HIV infection. Antiviral Research 57: 41, Feb 2003
31. Hemispherx Biopharma Inc. Hemispherx Presents New Data from Phase IIB Clinical Trial of RNA-based Ampligen® for Structured Treatment Interruption in HIV at DART Conference. Media Release: 17 Dec 2002. Available from URL: http://www.hemispherx.net